Use of Raltegravir in Pediatric HIV-1 Infection
Treatment options for pediatric patients with HIV-1 infection continue to expand. According to the updated Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection published in August 2011, 17 antiretroviral drugs have a pediatric indication from the Food and Drug Administration (FDA). On December 21, 2011, this number grew again as the FDA extended the approval of raltegravir to include children and adolescents from 2 to 18 years of age. Raltegravir was originally approved in 2007 for use in combination with other antiretroviral agents in adults with HIV-1 infection. It is currently the only HIV-1 integrase strand transfer inhibitor (INSTI) available in the United States and offers a safe and effective option for initial therapy for HIV-1 infection or treatment of patients with multidrug-resistant viral mutations.
Abstract and Introduction
Introduction
Treatment options for pediatric patients with HIV-1 infection continue to expand. According to the updated Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection published in August 2011, 17 antiretroviral drugs have a pediatric indication from the Food and Drug Administration (FDA). On December 21, 2011, this number grew again as the FDA extended the approval of raltegravir to include children and adolescents from 2 to 18 years of age. Raltegravir was originally approved in 2007 for use in combination with other antiretroviral agents in adults with HIV-1 infection. It is currently the only HIV-1 integrase strand transfer inhibitor (INSTI) available in the United States and offers a safe and effective option for initial therapy for HIV-1 infection or treatment of patients with multidrug-resistant viral mutations.
SHARE
